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Editorial on the Research Topic
NK Cell Subsets in Health and Disease: New Developments
Natural killer (NK) cells were discovered ca 1975, as the first group of lymphoid cells that were 
neither T cells nor B cells. Since then, the dissection of the biology of NK cells has been growing 
exponentially with many seminal discoveries from the identification of MHC class I-specific inhibi-
tory receptors to the discovery of receptor–ligand pairs involved in NK cell activation and to the 
manipulation of NK cells in cancer.
In this research topic, we asked a group of thought leaders in NK cell biology to review recent 
advances in their origins and biology, and their roles in cancer, infection, and inflammation.
Together, these 25 articles provide a timely survey of NK cells as critical immunologic compo-
nents of health and disease. They will hopefully prompt further dialog and developments in basic 
and translational immunology.
NK CEll oriGiNS aNd BioloGY
Nowadays, NK  cells are recognized to belong to the family of innate lymphoid cells (ILCs) that 
include other subsets of lymphoid cells, such as Lymphoid Tissue-inducer cells (LTi), ILC1, ILC2, 
and ILC3 (Jiao et al.). Human NK cells normally constitute 5–15% of human peripheral blood (PB) 
lymphocytes. Human PB NK cells can be distinguished in two subsets according to their surface 
expression of CD56: CD56bright and CD56dim. CD56bright human NK cells express high levels of CD94/
NKG2A but low levels of CD16 and lack of KIRs; they predominate in lymph nodes and express low 
baseline levels of perforin and cytotoxic activity. In addition they produce high levels of cytokines, 
including IFN-γ, following stimulation by pro-inflammatory cytokines. On the other hand, CD56dim 
NK cells are CD16high and express KIRs and/or CD94/NKG2A; they predominate in PB (about 90% of 
PB NK cells); they show high baseline levels of perforin and cytotoxicity against tumor/virus-infected 
target cells; and they also produce various cytokines in response to direct target cell interactions 
(Scoville et al.). A third NK cell subset is represented by the CD16+CD56neg NK cells, that are poorly 
functional, express low levels of natural cytotoxicity receptors (NCRs) and Siglec-7 (an inhibitory 
lectin-type receptor expressed on the majority of NK  cells) and may become more abundant in 
PB during persistent inflammation, characterizing several human chronic immunological diseases 
(such as viral infections and autoimmune diseases) (Mikulak et al.).
It has been recently demonstrated that the developmental pathways for NK cell and ILC develop-
ment are distinct; however, the developmental relationship between the different types of human 
NK subsets has not been finally clarified. While long held to represent sequential linear stages 
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in maturation, more recent hypotheses propose that CD56bright 
NK  cells may represent NK  cells activated in  vivo and/or that 
PB NK cell subpopulations derive from different hematopoietic 
progenitor cells. In this context, a recent study using genetic bar 
coding of NK cell lineages in rhesus macaques was suggestive 
of the two subsets having distinct ontologies (Scoville et al.). In 
addition, the recent characterization of a novel CD34+DNAM-
1brightCXCR4+ precursor in PB of patients with chronic inflamma-
tory conditions giving rise to apparently licensed and functional 
maturing NK  cells may suggest the possibility for a higher 
than expected common lymphocyte precursor diversity and a 
consequently higher peripheral NK  cell phenotype variability 
(Bozzano et al.).
Despite the existence of alternative hypotheses for NK  cell 
development, continually accumulating evidence suggest that a 
least fraction of CD56bright NK cells represent direct physiologic 
precursors of CD56dim NK cells. During their process of differen-
tiation, CD56dim NK cells lose expression of CD94/NKG2A and 
subsequentially acquire inhibitory KIRs and LIR-1, in addition 
they upregulate T-bet and downregulate Eomes, two key tran-
scription factors regulating NK  cell maturation and function 
during the last steps of their differentiation. In this context, it has 
been demonstrated that although the number of KIRs correlates 
with the extent of T-bet/Eomes modulation, “the modulation of 
these T-box transcription factors during NK cell maturation does 
not depend on signals conveyed by KIR” (Pradier et al.; Simonetta 
et al.). The terminally differentiated phenotype of CD56dim cells is 
marked by the expression of the CD57 molecule that is associated 
with poor ability to respond to cytokine-mediated stimulation, 
but preserved cytolytic capacity (Scoville et  al.; Bozzano et  al.; 
Della Chiesa et al.).
Notably, within the total CD56bright NK cell subset, a pheno-
typic and functional heterogeneity can be observed, as shown by 
the existence of tissue-resident CD56bright NK cells in the uterus/
maternal decidual, liver, and lymphoid tissues, where these cells 
exert tissue-specific functions. Uterine CD56bright NK cells express 
CD49a while the liver- and lymphoid tissue-resident CD56bright 
NK cells co-express CD69 and CXCR6. There is increasing evi-
dence that decidual NK (dNK) cells are crucial for pregnancy. 
Recent data demonstrate that the functions of dNK cells could 
be suppressed by a reduced HLA-G expression on extravillous 
trophoblasts suggesting a possible mechanism of recurrent 
miscarriage (Melsen et al.; Guo et al.). Finally, CD56bright NK cells 
may also play a major role in controlling T  cell responses and 
maintaining homeostasis. In this context, disorder in the regula-
tion function of NK cells has been recently described in patients 
with untreated multiple sclerosis (MS), indicating a possible role 
of this subset in the MS pathogenesis (Gross et al.).
NK CEllS aNd VirUSES
In recent years, it has been appreciated how infection with human 
cytomegalovirus (HCMV) can shape the NK cell receptor rep-
ertoire by inducing an increased frequency of a CD57+ NK cell 
population expressing CD94/NKG2C, the activating counterpart 
of CD94/NKG2A. This HCMV-induced NK cell subset is char-
acterized by the CD56dimCD16brightLIR-1+KIR+NKG2A− surface 
phenotype and expresses KIRs interacting with self-HLA 
class I molecules. In addition, these NK cells can display some 
hallmarks of adaptive immunity, such as, enhanced effector 
function, longevity, clonal expansion as well as given epigenetic 
modifications, including epigenetic remodeling at the IFNG 
locus, decreased expression of certain signaling molecules (i.e., 
the adaptor protein FcRγ and the tyrosine kinase Syk), and lower 
expression levels of the transcription factor PLZF. The higher 
accessibility of the IFNG locus can increase IFN-γ production 
upon target stimulation, while the lack of FcRγ can induce 
killing via antibody-dependent cellular cytotoxicity (ADCC) of 
opsonized HCMV-infected targets by adaptive NKG2C+ NK cells 
(Della Chiesa et  al.). HCMV infection also contributes to age-
associated changes in NK  cells. In particular, CMV infection 
and age induce significant changes in the expression of certain 
markers including CD300a, CD161, T-bet, and Eomes in the 
CD57+ NK cell subset (Lopez-Sejas et al.). Interestingly, HCMV 
infection may also favor the generation of a recently identified 
fully mature NK cell subset, characterized by the CD56dimKIR+ 
LIR-1+NKG2A− CD57+ phenotype, by a marked downregulation 
of NCRs and by the unexpected expression of the inhibitory PD-1 
immune checkpoint. PD-1+ NK  cells are also present, and in 
higher proportions as compared to PB of healthy donors, in both 
PB and ascitic fluids of ovarian-carcinoma patients suggesting 
their possible induction/enrichment in the microenvironment 
associated to the tumor. This phenotype correlates with an 
impaired NK cell activity toward PD-L+ tumor cells that can be 
partially restored by antibody-mediated disruption of PD-1/PD-L 
interaction. Importantly, the simultaneous blockade of PD-1 and 
KIR could amplify the NK-mediated anti-tumor activity. Due to 
the ineffective anti-tumor functions of this PD-1+ NK cell subset, 
it will be important to carefully evaluate the requirements that 
can lead to the generation of these cells in health and disease and 
to understand its role, in particular in patients with advanced 
cancers (Della Chiesa et al.).
Similar to HCMV infection, Epstein-Barr virus (EBV) 
infection may change the composition of NK  cells. “Early-
differentiated NK cells that expand during EBV infection might 
directly recognize lytically EBV replicating targets, while the 
terminally differentiated NK cells in HCMV-infected individu-
als mainly promote ADCC” (Chijioke et al.). Finally, the role of 
human NK cells in herpesviral control is accentuated by inherent 
genetic defects of immunity that lead to NK  cell aberrations a 
majority of which have impact upon specific NK  cell subsets 
(Mace and Orange). There is still much to be learned from these 
rare individuals with regard to specific NK cell populations and 
their role in human host defense.
NK CEllS aNd tUMorS
Natural killer cell-mediated ADCC plays an important role not 
only in the control of infections but also of tumors and down-
regulation of CD16 expression on activated NK cells may limit or 
regulate this response. In this context, in has been demonstrated 
that CD56dim CD57+ NK  cells are particularly prone to losing 
CD16 after influenza vaccination. This event supports a role for 
CD16 in early activation of NK  cells after vaccination and for 
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CD16 downregulation as a means to modulate NK cell responses 
and maintain immune homeostasis of both antibody and T cell-
dependent pathways (Goodier et al.).
Several data indicate that the microenvironment, the cytokine 
milieu, and genetic factors in cancer patients can exert a strong 
influence on NK cell receptor expression and functional poten-
tial (Carrega and Ferlazzo). Thus, the phenotype of the NK cell 
subpopulation associated with cancer may vary according to 
the specific kind of tumor and its anatomical location. In this 
context, chemokines/chemokine receptors play a critical role in 
the regulation of the distribution of NK cell subpopulations in 
the various tissues. Remarkably in different tumor types (includ-
ing lung cancer and melanoma), both migration and homing of 
NK cells may be altered and even reversed. For example, NK cells 
present in the tumor microenvironment are often enriched 
in CD56brightCD16neg/dim NK  cells (Carrega and Ferlazzo); in 
contrast, in melanoma metastatic lymph nodes, it is possible to 
detect the expansion of an unusual subset characterized by a 
CD56dim CD69+CCR7+ KIR+ phenotype (Cristiani et al.; Pesce 
et  al.). A likely explanation of these events is that the release 
of different types of chemokines by cells of the tumor micro-
environment, or the acquisition of different/new chemokine 
receptors by NK cells, can lead to an altered recruitment of the 
NK cell subpopulations.
traNSlatiNG BaSiC NK CEll BioloGY 
iNto tHE CliNiCS
Natural killer cells may display alloreactive potential in case 
of mismatch between recipient inhibitory KIRs and graft HLA 
class I molecules. Several studies have addressed the impact of 
this variable in the context of hematopoietic stem cell (HSC) 
and solid organ transplantation (including kidney transplant). 
In this context, several lines of evidence support that “adaptive” 
NKG2C+ NK  cells may contribute to control viral infection in 
HSC as well as in kidney transplant recipients. On the other hand, 
increasing evidence supports that alloantibody-mediated NK cell 
activation via FcγRIIIA (CD16) may contribute to rejection in 
kidney transplant recipients. Further studies integrating pheno-
typic, functional, and genetic analysis of NK cells should provide 
valuable insights on the pathogenesis of solid organ transplant 
complications (Lopez-Botet et al.; Legris et al.). Importantly, in 
addition to NK cells, ILCs may also represent important players 
in the early phases after transplantation (Vacca et al.).
A major goal of cancer immunotherapy based on the use of 
NK  cells is to reverse the tumor-induced NK  cell impairment 
observed in cancer patients and to amplify NK cell effector func-
tions. Therapies involving NK cells may either activate endogenous 
NK cells or involve transfer of exogenous pre-activated NK cells. 
In order to optimally harness NK cells in the next generation of 
NK  cell-based vaccines and therapeutics single-cell studies of 
the variety of antigens that can lead to NK cell diversification, the 
definition of the significance of the human NK repertoire in the 
context of viral infection and tumors will be extremely important 
(Strauss-Albee and Blish). Many NK  cell-based immunothera-
pies have been developed over the last decades, with allogeneic 
or autologous NK  cells. In 2005, haploidentical NK  cells were 
administered in a non-transplantation setting and resulted in 
a substantial improvement of patient clinical outcome and a 
substantive number of trials have followed. More recently, in vivo 
targeting of NK cells with antibodies was investigated: IPH2101 
is a first-in-class anti-KIR antibody that blocks inhibitory KIR–
ligand interactions, leading to restoration of NK cell functions. 
A phase II trial in acute myeloid leukemia elderly patients in 
first CR1 (NCT01687387) is in progress and several other trials 
are ongoing in different cancers alone or in combination with 
other treatments. The future introduction of a first-in-class anti-
NKG2A blocking antibody (IPH2201) will also provide a novel 
strategy to enhance tumor cell recognition (Rey et al.; Chabannon 
et al.). Remarkably, the recent discovery that a subset of NK cells 
may express PD-1 open prospects for extending the potential 
of cancer immunotherapy, by combining drugs blocking PD-1 
(or its major ligand PD-L1), with additional antibodies against 
immune checkpoints (KIR and NKG2A) expressed on this 
important innate effector cells (Della Chiesa et al.).
Natural killer cells can also be adoptively transferred 
following solid modifications in order to license them with 
new or reinforce functions and ensure their controlled 
persistence and activity in the recipient. In this context, it is 
crucial to analyze NK cell features in tumor patients in order 
to indicate a timeline when NK-mediated therapies or other 
immunotherapies could be performed (Rey et  al.). Ongoing 
developments for innovative cellular therapies suggest that 
such progress could result in wider clinical applications in 
the next future (Chabannon et al.). We believe that a deeper 
investigation into the impact of both conventional (e.g., 
chemotherapy) and new therapies (e.g., anti-immune check-
points antibodies) on NK cell homeostasis in cancer patients 
is now required.
A novel strategy to improve NK  cell-mediated immunosur-
veillance is to enable a proper NK cell migration to target tissues 
(including tumor sites) by promoting the expression of certain 
chemoattractant receptors on NK cells to be used for adoptive 
immunotherapy. In this context, NK cells engineered ex vivo to 
express chemokine receptors by gene transfer or by trogocytosis 
are under investigation for their better tissue homing and func-
tion (Pesce et al.; Bernardini et al.). For example, the acquisition 
of CCR7 expression by CD56dim KIR+ NK cells may play a key role 
in promoting the migration of this subset to lymph nodes, where 
CD56dim KIR+ NK cells may shape adaptive immune responses 
by leading to Th1 polarization (through the release of IFNγ and 
the mechanism of DC “editing”) but may also prevent GvHD 
and HvGD in haplo-HSCT by directly killing patient’s DCs and 
T cells (Pesce et al.). Thus, NK cells can affect DC fate and thereby 
control T cell responses (Pallmer and Oxenius).
In conclusion, we express our gratitude to all the authors who 
have contributed to this research topic and to the reviewers for 
their valuable work.
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